{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:03:57Z","timestamp":1773277437373,"version":"3.50.1"},"reference-count":36,"publisher":"The Pediatric Pharmacy Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:p>Spinal muscular atrophy (SMA) is a debilitating disorder characterized by degeneration of large motor neurons. It is a heterogeneous group of disorders caused by a homozygous deletion in the survival motor neuron (<jats:italic>SMN<\/jats:italic>) gene on chromosome 5, resulting in a SMN protein deficiency. Small amounts of SMN protein are also produced by the <jats:italic>SMN2<\/jats:italic> gene, which that differs from <jats:italic>SMN1<\/jats:italic> by a single nucleotide. Spinal muscular atrophy types and phenotypic severity depend on the number of variations of the <jats:italic>SMN2<\/jats:italic> gene and the amount of SMN2 protein produced. Because the SMN protein deficiency is the root cause of the disease, treatment strategies for SMA revolve around increasing SMN protein production. Nusinersen (Spinraza, Biogen, Cambridge, MA) was the only treatment option available for SMA until the FDA approved onasemnogene abeparvovec-xioi (Zolgensma, AveXis Inc, Bannockburn, IL), a one-time\u2013administered adeno-associated viral vector\u2013based gene therapy that delivers the <jats:italic>SMN<\/jats:italic> gene to the motor neuron cells. Data from clinical studies show significant improvement in motor milestone achievements and ventilator-free survival but are limited by approximately 5 years' worth of results. This one-time intravenous injection of this new gene therapy also bears a hefty price tag; however, it may be more cost effective in the long run versus the multiple intrathecal administrations needed with nusinersen. Drug access and use are hindered by drug cost, payer reimbursement issues, and lack of long-term data from clinical studies. Questions also remain regarding the safety and efficacy of repeated drug administration for patients with advanced disease.<\/jats:p>","DOI":"10.5863\/1551-6776-26.5.437","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T22:42:59Z","timestamp":1624920179000},"page":"437-444","source":"Crossref","is-referenced-by-count":14,"title":["Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy"],"prefix":"10.5863","volume":"26","author":[{"given":"Aimen","family":"Naveed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillary","family":"Calderon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"2","key":"i1551-6776-26-5-437-b1","series-title":"Neurotherapeutics","first-page":"290","article-title":"The genetics of spinal muscular atrophy: progress and challenges","volume":"12","year":"2015","unstructured":"Farrar\n              MA,\n            \n            \n              Kiernan\n              MC.\n            \n          \n          The genetics of spinal muscular atrophy: progress and challenges.\n\t\t\t\t\tNeurotherapeutics.\n\t\t\t\t\t2015;\n\t\t\t\t\t12(\n\t\t\t\t\t2):\n\t\t\t\t\t290\u2013\n\t\t\t\t\t302."},{"issue":"11","key":"i1551-6776-26-5-437-b2","series-title":"Int J Neurosci","first-page":"1","article-title":"Spinal muscular dystrophy\u2014a revisit of the diagnosis and treatment modalities","volume":"128","year":"2019","unstructured":"Srivastava\n              G,\n            \n            \n              Srivastava\n              P.\n            \n          \n          Spinal muscular dystrophy\u2014a revisit of the diagnosis and treatment modalities.\n\t\t\t\t\tInt J Neurosci.\n\t\t\t\t\t2019;\n\t\t\t\t\t128(\n\t\t\t\t\t11):\n\t\t\t\t\t1\u2013\n\t\t\t\t\t16."},{"issue":"1","key":"i1551-6776-26-5-437-b3","series-title":"J Pediatr","first-page":"155","article-title":"Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy","volume":"162","year":"2013","unstructured":"Farrar\n              MA,\n            \n            \n              Vucic\n              S,\n            \n            \n              Johnston\n              HM,\n            \n          \n          .\n\t\t\t\t\tPathophysiological insights derived by natural history and motor function of spinal muscular atrophy.\n\t\t\t\t\tJ Pediatr.\n\t\t\t\t\t2013;\n\t\t\t\t\t162(\n\t\t\t\t\t1):\n\t\t\t\t\t155\u2013\n\t\t\t\t\t159."},{"issue":"3","key":"i1551-6776-26-5-437-b4","series-title":"Ann Neurol","first-page":"355","article-title":"Emerging therapies and challenges in spinal muscular atrophy","volume":"81","year":"2017","unstructured":"Farrar\n              MA,\n            \n            \n              Park\n              SB,\n            \n            \n              Vucic\n              S,\n            \n          \n          .\n\t\t\t\t\tEmerging therapies and challenges in spinal muscular atrophy.\n\t\t\t\t\tAnn Neurol.\n\t\t\t\t\t2017;\n\t\t\t\t\t81(\n\t\t\t\t\t3):\n\t\t\t\t\t355\u2013\n\t\t\t\t\t368."},{"issue":"8","key":"i1551-6776-26-5-437-b5","series-title":"J Child Neurol","first-page":"1027","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","year":"2007","unstructured":"Wang\n              CH,\n            \n            \n              Finkel\n              RS,\n            \n            \n              Bertini\n              ES,\n            \n          \n          .\n\t\t\t\t\tConsensus statement for standard of care in spinal muscular atrophy.\n\t\t\t\t\tJ Child Neurol.\n\t\t\t\t\t2007;\n\t\t\t\t\t22(\n\t\t\t\t\t8):\n\t\t\t\t\t1027\u2013\n\t\t\t\t\t1049."},{"issue":"6","key":"i1551-6776-26-5-437-b6","series-title":"Nat Rev Neurol","first-page":"351","article-title":"Spinal muscular atrophy\u2014recent therapeutic advances for an old challenge","volume":"11","year":"2015","unstructured":"Faravelli\n              I,\n            \n            \n              Nizzardo\n              M,\n            \n            \n              Comi\n              GP,\n            \n            \n              Corti\n              S.\n            \n          \n          Spinal muscular atrophy\u2014recent therapeutic advances for an old challenge.\n\t\t\t\t\tNat Rev Neurol.\n\t\t\t\t\t2015;\n\t\t\t\t\t11(\n\t\t\t\t\t6):\n\t\t\t\t\t351\u2013\n\t\t\t\t\t359."},{"issue":"3","key":"i1551-6776-26-5-437-b7","series-title":"Neuromuscul Disord","first-page":"155","article-title":"The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability","volume":"20","year":"2010","unstructured":"Glanzman\n              AM,\n            \n            \n              Mazzone\n              E,\n            \n            \n              Main\n              M,\n            \n          \n          .\n\t\t\t\t\tThe Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability.\n\t\t\t\t\tNeuromuscul Disord.\n\t\t\t\t\t2010;\n\t\t\t\t\t20(\n\t\t\t\t\t3):\n\t\t\t\t\t155\u2013\n\t\t\t\t\t161."},{"issue":"2","key":"i1551-6776-26-5-437-b8","series-title":"Ann Clin Transl Neurol","first-page":"132","article-title":"Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study","volume":"3","year":"2016","unstructured":"Kolb\n              SJ,\n            \n            \n              Coffey\n              CS,\n            \n            \n              Yankey\n              JW,\n            \n          \n          .\n\t\t\t\t\tBaseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study.\n\t\t\t\t\tAnn Clin Transl Neurol.\n\t\t\t\t\t2016;\n\t\t\t\t\t3(\n\t\t\t\t\t2):\n\t\t\t\t\t132\u2013\n\t\t\t\t\t145."},{"issue":"9\u201310","key":"i1551-6776-26-5-437-b9","series-title":"Neuromuscul Disord","first-page":"693","article-title":"An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients","volume":"17","year":"2007","unstructured":"O'Hagen\n              JM,\n            \n            \n              Glanzman\n              AM,\n            \n            \n              McDermott\n              MP,\n            \n          \n          .\n\t\t\t\t\tAn expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients.\n\t\t\t\t\tNeuromuscul Disord.\n\t\t\t\t\t2007;\n\t\t\t\t\t17(\n\t\t\t\t\t9\u201310):\n\t\t\t\t\t693\u2013\n\t\t\t\t\t697."},{"issue":"2","key":"i1551-6776-26-5-437-b10","series-title":"Muscle Nerve","first-page":"157","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","year":"2015","unstructured":"Arnold\n              WD,\n            \n            \n              Kassar\n              D,\n            \n            \n              Kissel\n              JT.\n            \n          \n          Spinal muscular atrophy: diagnosis and management in a new therapeutic era.\n\t\t\t\t\tMuscle Nerve.\n\t\t\t\t\t2015;\n\t\t\t\t\t51(\n\t\t\t\t\t2):\n\t\t\t\t\t157\u2013\n\t\t\t\t\t167."},{"issue":"2","key":"i1551-6776-26-5-437-b11","series-title":"Neuromuscul Disord","first-page":"103","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","year":"2018","unstructured":"Mercuri\n              E,\n            \n            \n              Finkel\n              RS,\n            \n            \n              Muntoni\n              F,\n            \n          \n          .\n\t\t\t\t\tDiagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care.\n\t\t\t\t\tNeuromuscul Disord.\n\t\t\t\t\t2018;\n\t\t\t\t\t28(\n\t\t\t\t\t2):\n\t\t\t\t\t103\u2013\n\t\t\t\t\t115."},{"issue":"3","key":"i1551-6776-26-5-437-b12","series-title":"J Pediatr Pharmacol Ther","first-page":"194","article-title":"Nusinersen: a novel antisense oligo-nucleotide for the treatment of spinal muscular atrophy","volume":"24","year":"2019","unstructured":"Neil\n              EE,\n            \n            \n              Bisaccia\n              EK.\n            \n          \n          Nusinersen: a novel antisense oligo-nucleotide for the treatment of spinal muscular atrophy.\n\t\t\t\t\tJ Pediatr Pharmacol Ther.\n\t\t\t\t\t2019;\n\t\t\t\t\t24(\n\t\t\t\t\t3):\n\t\t\t\t\t194\u2013\n\t\t\t\t\t203."},{"key":"i1551-6776-26-5-437-b13","series-title":"Spinraza (nusinersen) injection for intrathecal use [package insert]","year":"2016","unstructured":"Spinraza (nusinersen) injection for intrathecal use [package insert].\n\t\t\t\t\tCambridge, MA:\n\t\t\t\t\tBiogen Inc;\n\t\t\t\t\t2016."},{"key":"i1551-6776-26-5-437-b14","series-title":"J Control Release","first-page":"94","article-title":"Gene therapy for the CNS using AAVs: the impact of systemic delivery by AAV9","volume":"241","year":"2016","unstructured":"Saraiva\n              J,\n            \n            \n              Nobre\n              RJ,\n            \n            \n              Pereira de Almeida\n              L.\n            \n          \n          Gene therapy for the CNS using AAVs: the impact of systemic delivery by AAV9.\n\t\t\t\t\tJ Control Release.\n\t\t\t\t\t2016;\n\t\t\t\t\t241:\n\t\t\t\t\t94\u2013\n\t\t\t\t\t109."},{"issue":"7","key":"i1551-6776-26-5-437-b15","series-title":"Mol Ther","first-page":"1187","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","year":"2009","unstructured":"Duque\n              S,\n            \n            \n              Joussemet\n              B,\n            \n            \n              Riviere\n              C,\n            \n          \n          .\n\t\t\t\t\tIntravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons.\n\t\t\t\t\tMol Ther.\n\t\t\t\t\t2009;\n\t\t\t\t\t17(\n\t\t\t\t\t7):\n\t\t\t\t\t1187\u2013\n\t\t\t\t\t1196."},{"issue":"4","key":"i1551-6776-26-5-437-b16","series-title":"Hum Mol Genet","first-page":"681","article-title":"Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice","volume":"20","year":"2011","unstructured":"Dominguez\n              E,\n            \n            \n              Marais\n              T,\n            \n            \n              Chatauret\n              N,\n            \n          \n          .\n\t\t\t\t\tIntravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.\n\t\t\t\t\tHum Mol Genet.\n\t\t\t\t\t2011;\n\t\t\t\t\t20(\n\t\t\t\t\t4):\n\t\t\t\t\t681\u2013\n\t\t\t\t\t693."},{"issue":"11","key":"i1551-6776-26-5-437-b17","series-title":"Mol Ther","first-page":"1971","article-title":"Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders","volume":"19","year":"2011","unstructured":"Bevan\n              AK,\n            \n            \n              Duque\n              S,\n            \n            \n              Foust\n              KD,\n            \n          \n          .\n\t\t\t\t\tSystemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders.\n\t\t\t\t\tMol Ther.\n\t\t\t\t\t2011;\n\t\t\t\t\t19(\n\t\t\t\t\t11):\n\t\t\t\t\t1971\u2013\n\t\t\t\t\t1980."},{"issue":"3","key":"i1551-6776-26-5-437-b18","series-title":"Nat Biotechnol","first-page":"271","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","year":"2010","unstructured":"Foust\n              KD,\n            \n            \n              Wang\n              X,\n            \n            \n              McGovern\n              VL,\n            \n          \n          .\n\t\t\t\t\tRescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN.\n\t\t\t\t\tNat Biotechnol.\n\t\t\t\t\t2010;\n\t\t\t\t\t28(\n\t\t\t\t\t3):\n\t\t\t\t\t271\u2013\n\t\t\t\t\t274."},{"issue":"18","key":"i1551-6776-26-5-437-b19","series-title":"New Engl J Med","first-page":"1713","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","year":"2017","unstructured":"Mendell\n              JR,\n            \n            \n              Al-Zaidy\n              S,\n            \n            \n              Shell\n              R,\n            \n          \n          .\n\t\t\t\t\tSingle-dose gene-replacement therapy for spinal muscular atrophy.\n\t\t\t\t\tNew Engl J Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t377(\n\t\t\t\t\t18):\n\t\t\t\t\t1713\u2013\n\t\t\t\t\t1722."},{"key":"i1551-6776-26-5-437-b20","series-title":"Mol Ther Methods Clin Dev","first-page":"87","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","year":"2018","unstructured":"Colella\n              P,\n            \n            \n              Ronzitti\n              G,\n            \n            \n              Mingozzi\n              F.\n            \n          \n          Emerging issues in AAV-mediated in vivo gene therapy.\n\t\t\t\t\tMol Ther Methods Clin Dev.\n\t\t\t\t\t2018;\n\t\t\t\t\t8:\n\t\t\t\t\t87\u2013\n\t\t\t\t\t104."},{"key":"i1551-6776-26-5-437-b21","series-title":"Pediatr Neurol.","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","article-title":"From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1","volume":"100","year":"2019","unstructured":"Al-Zaidy\n              SA,\n            \n            \n              Mendell\n              JR.\n            \n          \n          From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.\n\t\t\t\t\tPediatr Neurol.2019Nov;\n\t\t\t\t\t100:\n\t\t\t\t\t3\u2013\n\t\t\t\t\t11.\n\t\t\t\t\tdoi:10.1016\/j.pediatrneurol.2019.06.007."},{"issue":"2","key":"i1551-6776-26-5-437-b22","series-title":"Pediatr Pulmonol","first-page":"179","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","year":"2019","unstructured":"Al-Zaidy\n              S,\n            \n            \n              Pickard\n              AS,\n            \n            \n              Kotha\n              K,\n            \n          \n          .\n\t\t\t\t\tHealth outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy.\n\t\t\t\t\tPediatr Pulmonol.\n\t\t\t\t\t2019;\n\t\t\t\t\t54(\n\t\t\t\t\t2):\n\t\t\t\t\t179\u2013\n\t\t\t\t\t185."},{"issue":"3","key":"i1551-6776-26-5-437-b23","series-title":"J Neuromuscul Dis","first-page":"307","article-title":"AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort","volume":"6","year":"2019","unstructured":"Al-Zaidy\n              SA,\n            \n            \n              Kolb\n              SJ,\n            \n            \n              Lowes\n              L,\n            \n          \n          .\n\t\t\t\t\tAVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort.\n\t\t\t\t\tJ Neuromuscul Dis.\n\t\t\t\t\t2019;\n\t\t\t\t\t6(\n\t\t\t\t\t3):\n\t\t\t\t\t307\u2013\n\t\t\t\t\t317."},{"key":"i1551-6776-26-5-437-b24","series-title":"Pediatr Neurol","first-page":"39","article-title":"Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy","volume":"98","year":"2019","unstructured":"Lowes\n              LP,\n            \n            \n              Alfano\n              LN,\n            \n            \n              Arnold\n              WD,\n            \n          \n          .\n\t\t\t\t\tImpact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy.\n\t\t\t\t\tPediatr Neurol.\n\t\t\t\t\t2019;\n\t\t\t\t\t98:\n\t\t\t\t\t39\u2013\n\t\t\t\t\t45."},{"key":"i1551-6776-26-5-437-b25","article-title":"Zolgensma\u00ae data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing. Novartis Gene Therapies","unstructured":"Zolgensma\u00ae data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing. Novartis Gene Therapies.\n\t\t\t\t\tAccessed March 27, 2020. https:\/\/www.novartis.com\/news\/media-releases\/zolgensma-data-shows-rapid-significant-clinically-meaningful-benefit-sma-including-prolonged-event-free-survival-motor-milestone-achievement-and-durability-now"},{"key":"i1551-6776-26-5-437-b26","article-title":"AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma\u00ae in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1. Novartis Gene Therapies","unstructured":"AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma\u00ae in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1. Novartis Gene Therapies.\n\t\t\t\t\tAccessed January 26, 2020. https:\/\/www.novartis.com\/news\/media-releases\/avexis-presents-new-data-epns-continuing-show-significant-therapeutic-benefit-zolgensma-prolonging-event-free-survival-now-5-years-age-patients-spinal-muscular"},{"key":"i1551-6776-26-5-437-b27","series-title":"ZOLGENSMA (onasemnogene abeparvovec-xioi) [package insert]","year":"2019","unstructured":"ZOLGENSMA (onasemnogene abeparvovec-xioi) [package insert].\n\t\t\t\t\tBannockburn, IL:\n\t\t\t\t\tAveXis, Inc;\n\t\t\t\t\t2019."},{"key":"i1551-6776-26-5-437-b28","article-title":"Information for the Public\u2014AVXS-101","unstructured":"Information for the Public\u2014AVXS-101.\n\t\t\t\t\tAccessed July 15, 2020. https:\/\/www.biosafety.be\/sites\/default\/files\/bbe18bvw6_infopub_en.pdf"},{"issue":"4","key":"i1551-6776-26-5-437-b29","series-title":"Hum Gene Ther","first-page":"314","article-title":"Recombinant adeno-associated viral integration and genotoxicity: insights from animal models","volume":"28","year":"2017","unstructured":"Chandler\n              RJ,\n            \n            \n              Sands\n              MS,\n            \n            \n              Venditti\n              CP.\n            \n          \n          Recombinant adeno-associated viral integration and genotoxicity: insights from animal models.\n\t\t\t\t\tHum Gene Ther.\n\t\t\t\t\t2017;\n\t\t\t\t\t28(\n\t\t\t\t\t4):\n\t\t\t\t\t314\u2013\n\t\t\t\t\t322."},{"issue":"3","key":"i1551-6776-26-5-437-b30","series-title":"Neuromuscul Disord","first-page":"197","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","year":"2018","unstructured":"Finkel\n              RS,\n            \n            \n              Mercuri\n              E,\n            \n            \n              Meyer\n              OH,\n            \n          \n          .\n\t\t\t\t\tDiagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics.\n\t\t\t\t\tNeuromuscul Disord.\n\t\t\t\t\t2018;\n\t\t\t\t\t28(\n\t\t\t\t\t3):\n\t\t\t\t\t197\u2013\n\t\t\t\t\t207."},{"issue":"1","key":"i1551-6776-26-5-437-b31","series-title":"J Mark Access Health Policy","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvovec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","year":"2019","unstructured":"Malone\n              DC,\n            \n            \n              Dean\n              R,\n            \n            \n              Arjunji\n              R,\n            \n          \n          .\n\t\t\t\t\tCost-effectiveness analysis of using onasemnogene abeparvovec (AVXS-101) in spinal muscular atrophy type 1 patients.\n\t\t\t\t\tJ Mark Access Health Policy.\n\t\t\t\t\t2019;\n\t\t\t\t\t7(\n\t\t\t\t\t1):\n\t\t\t\t\t1601484.\n\t\t\t\t\tdoi:10.1080\/20016689.2019.1601484"},{"key":"i1551-6776-26-5-437-b32","article-title":"Spinraza\u00ae and Zolgensma\u00ae for Spinal Muscular Atrophy: Effectiveness and Value. Accessed July 15, 2020","unstructured":"Ellis\n              AG,\n            \n            \n              Mickle\n              K,\n            \n            \n              Herron-Smith\n              S,\n            \n          \n          .\n\t\t\t\t\tSpinraza\u00ae and Zolgensma\u00ae for Spinal Muscular Atrophy: Effectiveness and Value. Accessed July 15, 2020.\n\t\t\t\t\thttps:\/\/icer.org\/assessment\/spinal-muscular-atrophy-2019\/"},{"key":"i1551-6776-26-5-437-b33","article-title":"Cure SMA webinar gives update on Zolgensma access, insurance, and \u2026 SMA News Today. 2019. Accessed January 29, 2020","unstructured":"Lopes\n              JM.\n            \n          \n          Cure SMA webinar gives update on Zolgensma access, insurance, and \u2026 SMA News Today. 2019. Accessed January 29, 2020.\n\t\t\t\t\thttps:\/\/smanewstoday.com\/2019\/09\/03\/cure-sma-webinar-gives-zolgensma-access-data-concerns\/"},{"key":"i1551-6776-26-5-437-b34","article-title":"Novartis announces AVXS-101 intrathecal study update. Novartis Gene Therapies","unstructured":"Novartis announces AVXS-101 intrathecal study update. Novartis Gene Therapies.\n\t\t\t\t\tAccessed March 26, 2020. https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-avxs-101-intrathecal-study-update"},{"key":"i1551-6776-26-5-437-b35","article-title":"AveXis Community Statement on Global Managed Access Program for AVXS-101","unstructured":"AveXis Community Statement on Global Managed Access Program for AVXS-101.\n\t\t\t\t\tNovartis Gene Therapies. Accessed March 27, 2020. https:\/\/www.novartis.com\/news\/media-releases\/avexis-community-statement-global-managed-access-program-avxs-101-0"},{"key":"i1551-6776-26-5-437-b36","article-title":"Roche's risdiplam showed significant improvement in motor function in people aged 2\u201325 with type 2 or 3 spinal muscular atrophy. Roche. 2020. Accessed March 30, 2020","unstructured":"Roche's risdiplam showed significant improvement in motor function in people aged 2\u201325 with type 2 or 3 spinal muscular atrophy. Roche. 2020. Accessed March 30, 2020.\n\t\t\t\t\thttps:\/\/www.roche.com\/media\/releases\/medcor-2020-02-06.htm"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/26\/5\/article-p437.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/26\/5\/437\/2855290\/i1551-6776-26-5-437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/26\/5\/article-p437.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/26\/5\/article-p437.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:45:05Z","timestamp":1747356305000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/26\/5\/article-p437.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":36,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-26.5.437","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}